Company news

Denali Therapeutics Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

November 6, 2023

Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV: IDS) in MPS II (Hunter Syndrome) at SSIEM 2023

August 29, 2023

Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

August 7, 2023

Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs

June 20, 2023

Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV: IDS) Treatment in MPS II (Hunter Syndrome)

June 19, 2023

Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

May 7, 2023

Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta

April 11, 2023

Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting

April 9, 2023

Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

February 26, 2023

Denali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium™

February 21, 2023

Denali Therapeutics Announces Presentations on Enzyme Transport Vehicle (ETV) Development Programs for MPS Diseases at the Upcoming WORLDSymposium™

February 14, 2023

Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by Sanofi

January 24, 2023

Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases

January 8, 2023

Denali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform Trial

December 4, 2022

Denali Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

November 2, 2022

Denali Therapeutics Announces Phase 1/2 Study Single Dose Healthy Volunteer Data with TAK-594/DNL593 (PTV: PGRN) and Progression to Enrolling Participants with FTD-GRN

October 31, 2022

Denali Therapeutics Announces Closing of a $316 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

October 23, 2022

Denali Therapeutics Announces Pricing of $275 Million Public Offering of Common Stock

October 18, 2022

Denali Therapeutics Announces Proposed Offering of Common Stock

October 17, 2022

Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated with LRRK2 Pathogenic Mutations

October 2, 2022

Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV: IDS) in MPS II (Hunter Syndrome) at SSIEM 2022

August 30, 2022

Denali Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

August 7, 2022

Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson’s Disease

May 30, 2022

Denali Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

May 4, 2022

Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in ALS by Sanofi

May 1, 2022

Denali Therapeutics Appoints Alexander Schuth as Chief Operating and Financial Officer as Steve Krognes Transitions to Denali Board of Directors

March 14, 2022

Denali Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of DNL593 (PTV: PGRN) for Frontotemporal Dementia-Granulin (FTD-GRN)

March 8, 2022

Denali Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

February 27, 2022

Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs

February 27, 2022

Denali Therapeutics Announces Continued Progress in DNL310 (ETV: IDS) Program for MPS II (Hunter Syndrome) Supporting Planned Initiation of Phase 2/3 Clinical Trial

February 9, 2022

Denali Therapeutics Announces Appointment of Erik Harris to Board of Directors

February 6, 2022

Denali Therapeutics Announces Presentations on DNL310 (ETV: IDS) Development Program in MPS II (Hunter Syndrome) at the Upcoming WORLDSymposium™

January 31, 2022

Denali Therapeutics Announces FDA Clinical Hold on DNL919 Investigational New Drug (IND) Application

January 12, 2022

Denali Therapeutics Announces Progression and Expansion of Broad Therapeutic Portfolio for Neurodegeneration and Expected Key Milestones in 2022

January 9, 2022

Denali Therapeutics Announces Strategic Partner Takeda Exercises Option to Co-Develop and Co-Commercialize DNL593 (PTV: PGRN)

November 16, 2021

Denali Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights

November 3, 2021

Denali Therapeutics Announces Positive Clinical Results and Regulatory Progress for Development Programs in Amyotrophic Lateral Sclerosis (ALS)

October 5, 2021

Denali Therapeutics Announces Upcoming Presentations on EIF2B Activator DNL343 and RIPK1 Inhibitor SAR443820/DNL788 at the 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting

September 28, 2021

Denali Therapeutics Appoints Katie Peng as Chief Commercial Officer

September 26, 2021

Denali Therapeutics Announces Initiation of Phase 1b Study of EIF2B Activator DNL343 in ALS

September 8, 2021

Denali Therapeutics Announces Publication in Cell on New Approach to Treat FTD-GRN

August 25, 2021

Denali Therapeutics Reports Second Quarter 2021 Financial Results and Business Highlights

August 3, 2021

Denali Therapeutics Announces Positive Interim Data from Phase 1/2 Study with ETV: IDS (DNL310) in Patients with the Lysosomal Storage Disease Hunter Syndrome (MPS II)

July 24, 2021

Denali Therapeutics to Present Interim Data from Phase 1/2 Study of ETV: IDS (DNL310) for the Potential Treatment of Hunter Syndrome at MPS 2021

July 14, 2021

Denali Therapeutics Announces Initiation of Phase 2 Study by Partner Sanofi of RIPK1-Inhibitor DNL758 (SAR443122) in Cutaneous Lupus Erythematosus (CLE) Patients

June 27, 2021

Denali Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights

May 2, 2021

Denali Therapeutics Presents Positive Results from Phase 1 and Phase 1b Studies of Its LRRK2 Inhibitor, BIIB122/DNL151, Supporting Late-Stage Development Plans in Parkinson’s Disease

April 30, 2021

Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion as President and Chief Commercial Officer

March 29, 2021

Denali Therapeutics Announces Fast Track Designation Granted by the U.S. FDA to ETV: IDS (DNL310) for the Treatment of Patients with Hunter Syndrome (MPS II)

March 10, 2021

Denali Therapeutics Reports Full Year 2020 Financial Results and Business Highlights

February 24, 2021

← Newer news releases · Older news releases →

Calls

Decks